Talk:Aripiprazole: Difference between revisions
>Nibbablaster3000 m Will keep fixing it |
>Nibbablaster3000 m Will keep fixing it |
(No difference)
| |
Revision as of 20:08, 7 November 2022
| Summary sheet: Aripiprazole |
| Aripiprazole | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||
| Common names | Aripiprazole, Abilify | ||||||||||||||||||||||||||||
| Systematic name | [[systematic name::7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one]] | ||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Aripiprazole (branded as Abilify, Aristada among others) is an atypical antipsychotic approved for the treatment of schizophrenia, psychosis, bipolar disorder, and along with an antidepressant to treat major depressive disorder.
Aripiprazole was developed by "Ostuka-group" from Japan as an improvement from first-generation antipsychotics. The active molecule was originally found by the US based Bristol-Myers Squibb.
Schizophrenia
The 2016 NICE guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after risperidone for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.[2] A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.[3]
Adverse effects
In adults, side effects with greater than 10% incidence include weight gain, headache, akathisia, insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness.[4][5][6][7][8] Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose.[7] A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.[9][10]
Uncontrolled movement such as restlessness, tremors, and muscle stiffness may occur.[7]
There seems to be no recreational ways for using aripiprazole.
- ↑ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac
- ↑ "Psychosis and schizophrenia in children and young people: recognition and management | Guidance and guidelines | NICE". NICE. October 2016.
- ↑ "Schizophrenia: aripiprazole prolonged-release suspension for injection | Guidance and guidelines | NICE". NICE. 24 July 2013.
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedDM - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedEMC - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedEMA - ↑ 7.0 7.1 7.2 Cite error: Invalid
<ref>tag; no text was provided for refs namedABILIFY - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedWebMD - ↑ "Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems". U.S. Food and Drug Administration (FDA). 3 May 2016. Retrieved 4 May 2016.
- ↑ Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. (February 2016). "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". Journal of Clinical Psychopharmacology. 36 (1): 63–70. doi:10.1097/JCP.0000000000000444. PMC 4700874
. PMID 26658263.